NanoViricides, Inc. (NNVC)
Stock Price:
$3.45 USD
-0.30 (-8.00%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
36.76M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-13.45M |
| Shares Out |
10.65M |
| EPS (ttm) |
-2.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$3.45 |
| Previous Close |
$3.75 |
| Change ($) |
-0.30 |
| Change (%) |
-8.00% |
| Day's Open |
3.69 |
| Day's Range |
3.35 - 3.76 |
| Day's Volume |
188,177 |
| 52-Week Range |
1.85 - 19.20 |
More Stats
| Market Cap |
36.76M |
| Enterprise Value |
24.19M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.65M |
| Float |
9.54M |
| EPS (basic) |
-2.39 |
| EPS (diluted) |
-2.39 |
| FCF / Share |
-1.19 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
776,833 |
| Short Ratio |
3.01 |
| Short % of Float |
8.15% |
| Beta |
0.67 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.91 |
| Revenue |
n/a |
| Operating Income |
-8.00M |
| Net Income |
-13.45M |
| Free Cash Flow |
-6.67M |
| Net Cash |
12.56M |
| Net Cash / Share |
1.18 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-14.83% |
| ROE |
-83.11% |
| ROIC |
-159.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
14.5
Current: $3.45
High
14.5
Target: 14.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -8.00 | -8.66 | -9.33 | -9.60 | -8.86 | -7.06 | -8.67 | -6.59 | -6.08 | -6.43 |
| Net Income | -13.45 | -8.42 | -8.56 | -10.30 | -10.72 | -2.20 | -13.60 | -8.88 | -6.21 | -6.48 |
| Shares Outstanding | 5.62 | 3.59 | 3.25 | 3.01 | 2.88 | 2.83 | 2.56 | 2.29 | 2.14 | 1.99 |
| Earnings Per Share | -2.39 | -2.35 | -2.64 | -3.43 | -3.80 | -1.80 | -5.40 | -3.80 | -3.00 | -3.20 |
| Operating Cash Flow | -6.67 | -6.80 | -7.78 | -7.90 | -6.83 | -6.21 | -6.33 | -5.80 | -4.22 | -4.51 |
| Capital Expenditures | -0.01 | -0.07 | -0.24 | -0.16 | -0.48 | -6.76 | -5.23 | -0.06 | -0.06 | -0.19 |
| Free Cash Flow | -6.67 | -6.88 | -8.02 | -8.06 | -7.31 | -12.97 | -11.56 | -5.86 | -4.28 | -4.70 |
| Cash & Equivalents | 13.71 | 2.56 | 7.08 | 15.10 | 24.16 | 31.47 | 36.70 | 13.92 | 14.27 | 9.22 |
| Total Debt | 1.14 | - | - | 3.96 | 8.61 | 7.18 | 4.04 | 3.47 | - | - |
| Net Cash / Debt | 12.56 | 2.56 | 7.08 | 11.14 | 15.55 | 24.29 | 32.66 | 10.46 | 14.27 | 9.22 |
| Assets | 23.91 | 13.45 | 18.55 | 27.00 | 36.63 | 44.19 | 43.86 | 16.41 | 15.63 | 10.76 |
| Liabilities | 2.16 | 2.85 | 0.88 | 6.68 | 13.59 | 12.40 | 20.49 | 8.40 | 1.78 | 0.59 |
| Book Value | 21.76 | 10.60 | 17.66 | 20.32 | 23.05 | 31.79 | 23.37 | 8.01 | 13.85 | 10.17 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NanoViricides, Inc. |
| Country |
United States |
| Employees |
17 |
| CEO |
Anil R. Diwan |
Stock Information
| Ticker Symbol |
NNVC |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: NNVC |
Description
NanoViricides, a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.